Study: NCT01840579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg
Description: Administered as an intravenous (IV) infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg
Description: Administered as an IV infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m^2
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m^2
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 75 mg/m^2
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m^2
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m^2
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 mg/mL/min
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5 mg/mL/min
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6 mg/mL/min
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6 mg/mL/min
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m^2
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 100 mg/m^2
Description: Administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab 1 mg/kg
Description: Administered as an IV infusion on Day 1 of every other 21-day cycle (every 42 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide 100 mg/m^2
Description: Administered as an IV infusion on Days 1, 2, and 3 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide 100 mg/m^2
Description: Administered as an IV infusion on Days 1, 2, and 3 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF (pegfilgrastim) 3.6 mg
Description: Administered as a subcutaneous injection on Day 4 of Cycle 1